



## ANNEX 1

### Response document for MHRA public consultation on the proposal to make Acnecide Face Gel and Acnecide Face Wash available from general sales outlets without prescription

Ref: ARM 98

#### Your details

Name: [REDACTED]

Position (if applicable): client services executive

Organisation (if applicable):

Email: [REDACTED]

**1. Do you consider that Acnecide Face Gel and Acnecide Face Wash should be available as General Sale List (GSL) medicines?**

Yes ☒ No ☐ Not sure ☐

Please provide any comments or evidence to support your response:

Yes. I have used Acnecide 5% bp topical gel since 2015 and can say that it has made a terrific improvement to my life and my acne which, with the assistance of Acnecide, is now limited to occasional hormonal outbreaks that the gel also helps to clear quickly. I had struggled with mild acne for years and the emotional impact was severely starting to affect me. Acnecide gel has made a tremendous difference. I have always found it completely safe to use and have experienced no side effects, combining the treatment with moisturiser to lessen any dryness that may occur, though dryness is not something that I can say that I have been troubled with. I believe that the gel could help so many others who are struggling with their skin and the emotional impact it can cause to better access a product that does genuinely help to control the condition. It is important to sufferers that they can buy a truly effective product with ease when they desperately need it but may not have easy access to a pharmacy.

**2. Do you have any specific comments on the leaflets or the labels provided in the public reclassification report for Acnecide Face Gel and Acnecide Face Wash?**

I believe the proposed labelling is correct and helpful. As a user I know that a once daily application is still effective and limits the chance of any irritation (as two daily applications which I have also tried has never led to any problems except a drying of the spots as they slowly started to clear).

**3. Do you have any other comments on the reclassification?**

It is important to recognise the emotional impact even mild cases of acne can have. I suffered for many years trying products that promised much but delivered little. I was always anxious and felt my confidence and wellbeing ebb away. The impact of finding Acnecide 5% bp, watching my skin

continuously improve and not experience any negative effects except occasional dryness easily corrected with a dab of moisturiser has been rather life changing. Acne is serious to the sufferer and often it feels as though people do not realise how devastating it can be to have the condition and, in addition, not find anything effective in the stores that can help. Everyone's skin responds differently to treatments, but if I had found this product in stores earlier when I began to have problems I could have saved myself years of unhappiness and disappointment. Please allow people the opportunity to help themselves with this condition and give wider access to Acnecide to people who may not know about it but could benefit from it hugely.

**4. The MHRA may publish consultation responses. Do you want your response to remain confidential?**

Yes ☐

Partially\* ☒

No ☐

\*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information, we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

\*I would like my name and email address to be kept private and confidential

Responses can be continued onto a separate page if required. This form should be returned by email ([reclassification@mhra.gov.uk](mailto:reclassification@mhra.gov.uk)) to arrive by **30 May 2019**. Contributions received after that date cannot be included in the exercise.